This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
30 Sep 2019
Troponin only Manchester Acute Coronary Syndromes (TMACS) Network Event
Health Innovation Manchester hosted a Troponin only Manchester Acute Coronary Syndromes (TMACS) Network event in Manchester, to update partners on the progress of the TMACS programme and share learning from the recent work that is being done across Greater Manchester.
Cara Azfal, Senior Programme Developement Lead at Health Innovation Manchester began by giving guests a presentation on the role of Health Innovation Manchester, and in the purpose of the event; setting the context before the background of the TMACS project was discussed.
Dr Richard Body, Director, Manchester Diagnostics and Technology Accelerator (DiTA), Manchester University NHS Foundation Trust, then presented on the background of the TMACS project and updated attendees on the progress that has been made already, whilst looking at where the project is at across the Greater Manchester sites.
Following this update, guests were invited to take part in a facilitated discussion to capture what progress there has been so far in their own experiences, the key challenges, and to discuss what has gone particularly well for them, or what could have gone better.
Next, Dr Stuart Monk, Associate Director at South West Academic Health Science Network (AHSN) gave an overview of the national High-sensitivity Troponin Programme, and the role of AHSNs in the spread and adoption of innovation.
Following Dr Monk, the next speaker to address guests on the day was Dr Patricia Van Den Berg, NIHR Academic Clinical Fellow in Emergency Medicine at the University of Manchester. Dr Van Den Berg gave a detailed presentation on shared decision making and the TMACS pathway.
The session was then concluded with a short Q&A session, chaired by Dr Monk, before Louise Bond, Programme Development Lead at Health Innovation Manchester discussed the next steps to close the network event.
Cara Azfal, Senior Programme Development Lead at Health Innovation Manchester, said: “As part of the HInM Cardiovascular portfolio we have been working at speed to take innovative initiatives in one part of Greater Manchester and spread wider. T-MACS is one example of a local innovation being spread wider across Greater Manchester, with interest nationally.
“This tool provides improved diagnostic testing accuracy for patients, to accelerate decision making and thereby support improved care for patients. I am proud to say that working with Prof Rick Body we have seen first-hand how strong clinical leadership is transforming improved care at speed.”